Larisa J. Geskin

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 580 citations

Medicine, Hematology, Oncology +12

The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

Julia Scarisbrick, Pietro Quaglino, H. Miles Prince et al. · British Journal of Dermatology · 2018 · 236 citations · Full text

Medicine, Oncology, Pathology +16

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

Gregory S. Phillips, Jennifer Wu, Matthew D. Hellmann et al. · Journal of Clinical Oncology · 2019 · 235 citations · Full text

Medicine, Dermatology, Immunology +17

Cutaneous T cell lymphoma

Reinhard Dummer, Maarten H. Vermeer, Julia Scarisbrick et al. · Nature Reviews Disease Primers · 2021 · 173 citations

Medicine, Hematology, Oncology +15